Department of Dermatology & Academic Wound Healing, Institute of Infection & Immunity, Cardiff University, Wales.
JAMA Dermatol. 2017 May 1;153(5):458-459. doi: 10.1001/jamadermatol.2017.0432.
Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults?
There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, -3.7 to -2.0 points) and 1.6 points (95% CI, -3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.
哪些治疗方法已在随机临床试验 (RCT) 中被证明对成人化脓性汗腺炎 (HS) 有效？
有高质量证据表明阿达木单抗每周给药有效，而每两周给药无效，与安慰剂相比，皮肤病生活质量指数 (DLQI) 评分分别降低 2.8 分（95%CI：-3.7 至-2.0 分）和 1.6 分（95%CI：-3.9 至 0.6 分）。质量中等的证据表明英夫利昔单抗是有益的；其他干预措施的 RCT 证据质量较低或不存在，限制了进一步的结论。
